Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

HAYWARD, Calif.–(BUSINESS WIRE)–Applied Biomics, Inc., a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage. Currently, the company provides Anti-CHO, Anti-HEK293 and Anti-E. coli HCP Antibodies.

The residual HCPs are generated by organisms used for making recombinant biopharmaceutical products. They are considered as process-related impurities. Since HCPs can potentially cause adverse effects, HCP antibodies with high HCP coverage are crucial for detecting HCPs in process development and product quality control. Following are highlights of Applied Biomics’ HCP Antibodies:

High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.

Broad Reactivity: Reacts with a wide range of host species strains. The Anti-CHO HCP antibody reacts with CHO-S, CHO-K1, CHO-GS, CHO-DG44, etc. The Anti-HEK293 antibody reacts well with not only HEK293, but also other human cell lines such as CAP, Hela, Per.C6, A549, MRC-5, etc.

Multiple applications: Can be used for 1D or 2D Western Blot, ELISA, and Immuno-precipitation.

Competitive pricing: Offered at a lower price (with same quantity) than similar antibodies from other vendors.

Excellent support: Backed by over 20 years of experience in antibody development and validation.

We believe these HCP antibodies provide a powerful tool in improving HCP analysis. With our leading HCP antibody coverage services, customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

About Applied Biomics

Applied Biomics is a Proteomics Service and Product company established in 2005. We are centrally located in San Francisco Bay Area.

Our services cover from complimentary experimental design, sample preparations, protein separations/quantifications to protein identifications and publication-ready data. Our proprietary experimental procedures have been optimized for every specific sample type and various applications.

We cover both major platforms of proteomics: Gel-based 2D DIGE (2-dimensional differential in-gel electrophoresis) and liquid-based LC-MS/MS. Our 2D Fluorescent Western Blot platform is the industry leader in evaluating HCP antibody coverage. We have served many biotech and pharmaceutical companies in testing HCP antibody coverage.

Contacts

Helen Hu

Director, Proteomics

[email protected]
510-887-0348